Influenza B Virus, Live Attenuated

CHEMBL6068387 Phase 4 Disetujui Vaccine component

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A weakened, live influenza B virus component used in nasal spray flu vaccines to induce broad immunity against influenza B. The attenuated virus replicates in the upper respiratory tract, stimulating both local and systemic immune responses.

Area Terapeutik

Respiratory Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A weakened, live influenza B virus component used in nasal spray flu vaccines to induce broad immunity against influenza B. The attenuated virus replicates in the upper respiratory tract, stimulating both local and systemic immune responses.

Yes, Influenza B Virus, Live Attenuated is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068387. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Mencari informasi yang ramah bagi pasien?

Influenza B Virus, Live Attenuated di PillFYI

Data Cepat

Tautan Eksternal

ChEMBL CHEMBL6068387

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.